These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 30462431)

  • 1. [The first results of assessment of clinical efficacy of melatonin and metformin in patients with disseminated skin melanoma receiving dacarbazine as first-line systemic therapy].
    Novik AV; Protsenko SA; Baldueva IA; Berstein LM; Anisimov VN; Semenova AI; Latipova DK; Tkachenko EV; Semiglazova TY
    Vopr Onkol; 2016; 62(2):324-9. PubMed ID: 30462431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma.
    Novik AV; Protsenko SA; Baldueva IA; Berstein LM; Anisimov VN; Zhuk IN; Semenova AI; Latipova DK; Tkachenko EV; Semiglazova TY
    Oncologist; 2021 May; 26(5):364-e734. PubMed ID: 33749049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
    Kefford RF; Clingan PR; Brady B; Ballmer A; Morganti A; Hersey P
    Mol Cancer; 2010 Mar; 9():69. PubMed ID: 20350333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
    Gershanovich ML; Akimov MA
    Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
    Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
    Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
    Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
    Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
    Luikart SD; Kennealey GT; Kirkwood JM
    J Clin Oncol; 1984 Mar; 2(3):164-8. PubMed ID: 6199481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
    Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
    J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
    J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.